ImmunoPrecise Antibodies Ltd.
IPA
$0.3918
-$0.0082-2.05%
| 10/31/2024 | 07/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 16.71% | -19.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.71% | -19.25% | |||
| Cost of Revenue | -7.27% | -14.03% | |||
| Gross Profit | 46.30% | -24.88% | |||
| SG&A Expenses | -2.65% | -8.43% | |||
| Depreciation & Amortization | 1.45% | -14.32% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.26% | -2.94% | |||
| Operating Income | 37.22% | -26.75% | |||
| Income Before Tax | 35.75% | 74.86% | |||
| Income Tax Expenses | 34.60% | 1.03% | |||
| Earnings from Continuing Operations | 35.98% | 78.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.98% | 78.04% | |||
| EBIT | 37.22% | -26.75% | |||
| EBITDA | 46.68% | -36.54% | |||
| EPS Basic | 38.20% | 78.44% | |||
| Normalized Basic EPS | 37.98% | -22.60% | |||
| EPS Diluted | 38.20% | 78.44% | |||
| Normalized Diluted EPS | 37.98% | -22.60% | |||
| Average Basic Shares Outstanding | 3.68% | 1.83% | |||
| Average Diluted Shares Outstanding | 3.68% | 1.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
